Abstract: A traffic analysis system monitors data traffic in a communication network. In the data traffic, flows are detected which are based on the Hypertext Transfer Protocol (HTTP). For each of the flows, a data record is created. The data record comprises at least a User Agent identifier from a message header of a HTTP message of the flow and a device identifier of a user equipment transmitting the flow. The data records are analyzed to determine a mapping of at least one User Agent identifier in the data records to a corresponding device category.

Abstract: A technique for predicting network load in a communication network is described. For multiple subscriptions, a network load snapshot is provided. The network load snapshot comprises multiple network load records. Each network load record reflects network load caused by an associated subscription in the network at a particular point of time. Each network load record comprises at least one network load value reflecting a network load caused by the corresponding subscription and at least one network load influencing factor reflecting a parameter associated with the subscription which has the potential of influencing the network load value. The network load snapshot is transformed into a predicted network load snapshot comprising at least one predicted network load record, each predicted network load record reflecting estimated network load caused by the corresponding subscription at a particular point of time in the future.

Abstract: Compounds of formula (I) having a selective dual action on the central GABAergic system, and a process for their preparation and to pharmaceutical compositions containing them.

Abstract: The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula —NH—SO2—R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

Abstract: A technique for predicting network load in a communication network is described. For multiple subscriptions, a network load snapshot is provided. The network load snapshot comprises multiple network load records. Each network load record reflects network load caused by an associated subscription in the network at a particular point of time. Each network load record comprises at least one network load value reflecting a network load caused by the corresponding subscription and at least one network load influencing factor reflecting a parameter associated with the subscription which has the potential of influencing the network load value. The network load snapshot is transformed into a predicted network load snapshot comprising at least one predicted network load record, each predicted network load record reflecting estimated network load caused by the corresponding subscription at a particular point of time in the future.

Abstract: The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.

Abstract: A traffic analysis system monitors data traffic in a communication network. In the data traffic, flows are detected which are based on the Hypertext Transfer Protocol (HTTP). For each of the flows, a data record is created. The data record comprises at least a User Agent identifier from a message header of a HTTP message of the flow and a device identifier of a user equipment transmitting the flow. The data records are analyzed to determine a mapping of at least one User Agent identifier in the data records to a corresponding device category.

Abstract: A technique for controlling data transmission over a connection employing congestion control is provided. The technique comprises two basic aspects: Detecting a decrease of Round Trip Time in respect of the connection, wherein the detection is facilitated by comparing a short-term Round Trip Time average with a long-term Round Trip Time average (302); and, in response to a result of the detection, adjusting the congestion control so as to increase the data transmission rate (304). Particularly, adjusting the congestion control includes enabling a data transmission rate that is (even) higher than what would have been allowed by any conventional, congestion control. In effect, the present technique may ‘push’ the conventional congestion control when it is not increasing the data transmission rate fast enough.

Abstract: The object of the present invention is a one-pot process for preparing the 2-acetoxy-5-(2-fluoro-?-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]-pyridine (prasugrel) of the formula (I) by reacting the 5,6,7,7a-tetrahydro-4H-tieno[3,2-c]-pyridine-2-on of the formula (II) with 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)-etanone of the formula (III) or with 2-chloro-1-cyclopropyl-2-(2-fluorphenyl)-etanone of the formula (IIIa) and acetylating of the formed compound of the formula (IV), wherein the reaction is carried out in the presence of an organic base with an acetylation agent without isolating the compound of the formula (IV). The coupling and acetylation are carried out in the presence of the same organic base such as triethylamine, N,N-diisopropyl-ethylamine or pyridine. At the end of the process the prasugrel of the formula (I) is purified by recrystallization from an organic solvent or a mixture of solvents.

Abstract: The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.

Abstract: The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula —NH—SO2—R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

Abstract: An apparatus for the production of ozone for an internal combustion engine comprising a non-conductive shell having a first and second opening which allows air to flow therethrough and first and second electrodes disposed inside the shell. The first electrode is spaced a distance from the second electrode, the first electrode having a smaller diameter than, and being aligned axially within the second electrode. The first electrode permits air to flow therethrough. A high voltage source is connected to the first and second electrode, the high voltage source capable of producing a voltage differential on the first and second electrodes sufficient to cause the production of ozone. A change from oxygen to ozone occurs in the air flowing through the apparatus. The shell is preferably cylindrical.

Abstract: A method of reducing buffer overflow in a cellular radio network caused by a transfer of data from a buffer in a first cell to a buffer in a second cell when a handover of mobile equipment from said first cell to said second cell occurs. The method comprises temporarily increasing an amount of temporary buffer space required to handle data transferred from the buffer of the first cell to the buffer of the second cell. In one embodiment of the method, prior to increasing the amount of temporary buffer space, the amount of temporary buffer space required is calculated.

Abstract: A throttle device is coupled with a central processing unit in a node for reducing traffic overload in a Next Generation Network (NGN). The device is coupled with a basic throttle with different levels of traffic priority and both are situated between a source node and a target node for processing traffic. When a traffic offer is received by the throttle, the throttle device by provisionally updating the basic throttle priority levels, determines whether to send the traffic offer on to the source node. If the provisional, traffic priority level is greater than a new traffic priority level the traffic is admitted and rejected if the updated priority level is less than the new traffic priority level.

Abstract: A throttle device is coupled with a central processing unit in a node for reducing traffic overload in a Next Generation Network (NGN). The device is coupled with a basic throttle with different levels of traffic priority and both are situated between a source node and a target node for processing traffic. When a traffic offer is received by the throttle, the throttle device by provisionally updating the basic throttle priority levels, determines whether to send the traffic offer on to the source node. If the provisional, traffic priority level is greater than a new traffic priority level the traffic is admitted and rejected if the updated priority level is less than the new traffic priority level.

Abstract: The invention relates to a process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]benzodiazepine (olanzapine) of the formula (I) by reacting 4-amino-2-methyl-10H-thieno[2,3-b][1/5]benzodiazepine hydrochloride of the formula (II) with N-methylpiperazine in an organic solvent, which comprises carrying out the reaction in the mixture of toluene and 1,3-dimethyl-2-imidazolidinone. The invention also encompasses new 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b] [1,5]benzodiazepine dihydrochloride trihydrate of the formula (IB), the preparation thereof and pharmaceutical compositions comprising said new compound.

Abstract: A technique for controlling data transmission over a connection employing congestion control is provided. The technique comprises two basic aspects: Detecting a decrease of Round Trip Time in respect of the connection, wherein the detection is facilitated by comparing a short-term Round Trip Time average with a long-term Round Trip Time average (302); and, in response to a result of the detection, adjusting the congestion control so as to increase the data transmission rate (304). Particularly, adjusting the congestion control includes enabling a data transmission rate that is (even) higher than what would have been allowed by any conventional, congestion control. In effect, the present technique may ‘push’ the conventional congestion control when it is not increasing the data transmission rate fast enough.

Abstract: A system, method and node for overload control in a network. The method includes the steps of receiving an incoming offer by a node, filtering the offer by an in-throttle to determine if the offer is permitted to be processed by the node prior to processing by the node, processing a permitted offer, and sending the processed offer to a designated target. After processing the permitted offer by the node, the offer may be further filtered prior to sending the offer to the designated target.

Abstract: An apparatus for the production of ozone for an internal combustion engine comprising a non-conductive shell having a first and second opening which allows air to flow therethrough and first and second electrodes disposed inside the shell. The first electrode is spaced a distance from the second electrode, the first electrode having a smaller diameter than, and being aligned axially within the second electrode. The first electrode permits air to flow therethrough. A high voltage source is connected to the first and second electrode, the high voltage source capable of producing a voltage differential on the first and second electrodes sufficient to cause the production of ozone. A change from oxygen to ozone occurs in the air flowing through the apparatus. The shell is preferably cylindrical.

Abstract: A system, method and node for overload control in a network. The method includes the steps of receiving an incoming offer by a node, filtering the offer by an in-throttle to determine if the offer is permitted to be processed by the node prior to processing by the node, processing a permitted offer, and sending the processed offer to a designated target. After processing the permitted offer by the node, the offer may be further filtered prior to sending the offer to the designated target.